{"entity":{"id":"nct03980054","kind":"trial","name":"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","aka":[],"tldr":"A phase 3 trial of Pyrotinib in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","summary":"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer is a phase 3 interventional study registered as NCT03980054 by Jiangsu HengRui Medicine Co., Ltd., with 2135 participants enrolled, started 2019-07-12 and due to reach its primary completion in 2027-06. Interventions recorded: Pyrotinib and Placebo.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03980054","url":"https://clinicaltrials.gov/study/NCT03980054"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pyrotinib"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03980054","phase":"3","setting":"A Phase III Study to Evaluate the Efficacy and Safety of Pyrotinib Versus Placebo in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":2135,"outcomes":[]},"route":"/trials/nct03980054/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}